表紙:20Sプロテアソーム:パイプライン製品の分析
市場調査レポート
商品コード
363576

20Sプロテアソーム:パイプライン製品の分析

20s Proteasome - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 76 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.26円
20Sプロテアソーム:パイプライン製品の分析
出版日: 2021年09月30日
発行: Global Markets Direct
ページ情報: 英文 76 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、20Sプロテアソーム薬剤の開発状況関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

20Sプロテアソームの概要

治療薬の開発

  • 20Sプロテアソーム:開発中の製品 - 開発段階別
  • 20Sプロテアソーム:開発中の製品 - 治療範囲別
  • 20Sプロテアソーム:開発中の製品 - 適応症別
  • 20Sプロテアソーム:開発中の製品 - 企業別
  • 20Sプロテアソーム:開発中の製品 - 大学・研究機関別

20Sプロテアソーム:治療薬の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

20Sプロテアソームの治療薬開発に従事している企業

  • Amgen Inc.
  • Celgene Corp

20Sプロテアソーム:薬剤プロファイル

20Sプロテアソーム:休止中のプロジェクト

20Sプロテアソーム:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Indications, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Amgen Inc, 2021
  • Pipeline by Bristol-Myers Squibb Co, 2021
  • Pipeline by Centrax International Inc, 2021
  • Pipeline by HuniLife Biotechnology Inc, 2021
  • Pipeline by Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd, 2021
  • Pipeline by Zymergen Inc, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Dormant Products, 2021 (Contd..2)

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
目次
Product Code: GMDHC2972TDB

Summary:

20s Proteasome pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report 20s Proteasome - Drugs In Development, 2021, outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Metabolic Disorders which include indications Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Amyloidosis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Gliosarcoma, Kidney Transplant Rejection, Leukemia, Lung Transplant Rejection, Malignant Glioma, Metastatic Renal Cell Carcinoma, Neuroendocrine Cancer, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Renal Cell Carcinoma, Tuberculosis and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Furthermore, this report also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for 20s Proteasome
  • The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects
  • The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 20s Proteasome targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 20s Proteasome Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • 20s Proteasome - Overview
  • 20s Proteasome - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • 20s Proteasome - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • 20s Proteasome - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Centrax International Inc
  • HuniLife Biotechnology Inc
  • Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd
  • Zymergen Inc
  • 20s Proteasome - Drug Profiles
  • carfilzomib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CX-13608 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HuL-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • marizomib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NNU-546 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RTSV-5 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit 20S Proteasome for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit 20s Proteasome for Tuberculosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TIR-199 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • 20s Proteasome - Dormant Products
  • 20s Proteasome - Product Development Milestones
  • Featured News & Press Releases
  • Jul 09, 2021: BeiGene announces the approval in China of KYPROLIS (Carfilzomib) for injection for adult patients with relapsed or refractory multiple myeloma
  • Mar 22, 2021: Triple therapy recommended by NICE for patients with multiple myeloma
  • Nov 30, 2020: Amgen announces new data on KYPROLIS At ASH 2020
  • Nov 12, 2020: CHMP adopts a positive opinion recommending a change to the terms of the marketing authorisation for Kyprolis
  • Aug 20, 2020: FDA approves new KYPROLIS (carfilzomib) combination regimen with DARZALEX (daratumumab) and Dexamethasone in both once- and twice-weekly dosing regimens
  • May 14, 2020: Oncolytics Biotech announces publication of abstract on Kyprolis at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
  • May 13, 2020: Amgen presents update on KYPROLIS at ASCO 2020
  • May 05, 2020: KYPROLIS (carfilzomib) patents upheld against generic manufacturer
  • Dec 11, 2019: Amgen reports positive data in multiple myeloma study
  • Dec 02, 2019: Amgen announces data to be presented on KYPROLIS (carfilzomib) at ASH 2019
  • Sep 13, 2019: Amgen announces phase 3 CANDOR study combining KYPROLIS (carfilzomib) and DARZALEX (daratumumab) meets primary endpoint of progression-free survival
  • Sep 12, 2019: Amgen highlights new data From KYPROLIS (carfilzomib) and Oncology Pipeline At IMW 2019
  • Aug 19, 2019: Carfilzomib (Kyprolis): reminder of risk of potentially fatal cardiac events
  • Jun 19, 2019: Early Indications of potential Heart Conditions Using Carfilzomib in Multiple Myeloma
  • Jun 13, 2019: Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer